Evista (raloxifene) can help prevent breast cancer in postmenopausal women with osteoporosis

There's growing evidence that Evista (raloxifene) can help prevent breast cancer in postmenopausal women with osteoporosis.

Evista is approved only to prevent or treat osteoporosis in postmenopausal women. But Evista might lead to a 60% reduction in breast cancer.

It's too soon to prescribe Evista to prevent breast cancer. Continue to use Evista for women who need treatment for osteoporosis...and consider breast cancer prevention a possible beneficial side effect.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote